110 related articles for article (PubMed ID: 20346005)
1. Bortezomib for the treatment of refractory Type-1 cryoglobulinaemia.
Spizzo G; Mitterer M; Gunsilius E
Br J Haematol; 2010 Jul; 150(2):235-7. PubMed ID: 20346005
[No Abstract] [Full Text] [Related]
2. Response to bortezomib in refractory type I cryoglobulinemia.
Talamo G; Claxton D; Tricot G; Fink L; Zangari M
Am J Hematol; 2008 Nov; 83(11):883-4. PubMed ID: 18756542
[No Abstract] [Full Text] [Related]
3. Efficacy of bortezomib in refractory form of multicentric Castleman disease associated to poems syndrome (MCD-POEMS variant).
Sobas MA; Alonso Vence N; Diaz Arias J; Bendaña Lopez A; Fraga Rodriguez M; Bello Lopez JL
Ann Hematol; 2010 Feb; 89(2):217-9. PubMed ID: 19636554
[No Abstract] [Full Text] [Related]
4. Bortezomib in lung transplantation: a promising start.
Neumann J; Schio S; Tarrasconi H; Bortolotto A; Costa C; Machuca T; Camargo S; Sanchez L; Michelon T; Canabarro R; Sporleder H; Fernandes S; Camargo J; Perin F; Felicetti J
Clin Transpl; 2009; ():421-4. PubMed ID: 20524308
[No Abstract] [Full Text] [Related]
5. Bortezomib for refractory antibody-mediated cardiac allograft rejection.
Eckman PM; Thorsgard M; Maurer D; Kim Y; Alloway RR; Woodle ES
Clin Transpl; 2009; ():475-8. PubMed ID: 20524318
[TBL] [Abstract][Full Text] [Related]
6. Drug-induced cutaneous vasculitis in patients with non-Hodgkin lymphoma treated with the novel proteasome inhibitor bortezomib: a possible surrogate marker of response?
Gerecitano J; Goy A; Wright J; MacGregor-Cortelli B; Neylon E; Gonen M; Esseltine D; Boral A; Schenkein D; Busam K; Teruya-Feldstein J; Sachs D; O'Connor OA
Br J Haematol; 2006 Aug; 134(4):391-8. PubMed ID: 16882131
[TBL] [Abstract][Full Text] [Related]
7. Bortezomib effectiveness in one patient with acquired von Willebrand syndrome associated to monoclonal gammopathy of undetermined significance.
Ojeda-Uribe M; Caron C; Itzhar-Baikian N; Debliquis A
Am J Hematol; 2010 May; 85(5):396. PubMed ID: 20425807
[No Abstract] [Full Text] [Related]
8. Bortezomib in multiple myeloma.
Meisler AI
N Engl J Med; 2003 Sep; 349(13):1287-8; author reply 1287-8. PubMed ID: 14510013
[No Abstract] [Full Text] [Related]
9. Bortezomib in the treatment of antibody-mediated rejection--a report of 3 cases.
Mai HL; Cesbron A; Brouard S; Blanchol G; Cantarovich D; Dantal J; Hourmant M; Lino M; Meurette A; Gosselin M; Abbadie O; Soulillou JP; Giral M
Clin Transpl; 2009; ():361-8. PubMed ID: 20524299
[No Abstract] [Full Text] [Related]
10. Effects of bortezomib on pro-inflammatory cytokine levels and transfusion dependency in a patient with multicentric Castleman disease.
Hess G; Wagner V; Kreft A; Heussel CP; Huber C
Br J Haematol; 2006 Sep; 134(5):544-5. PubMed ID: 16856889
[No Abstract] [Full Text] [Related]
11. Acute humoral rejection in a lung recipient: reversion with bortezomib.
Neumann J; Tarrasconi H; Bortolotto A; Machuca T; Canabarro R; Sporleder H; Fernandes S; Schio S; Costa C; Camargo S; Sanchez L; Camargo J; Perin F; Felicetti J; Michelon T
Transplantation; 2010 Jan; 89(1):125-6. PubMed ID: 20061929
[No Abstract] [Full Text] [Related]
12. Use of bortezomib for prevention and treatment of rejection in sensitized patients.
Hartono C; Lubetzky M; Aull MJ; Saal S; Figueiro J; Kapur S; Dadhania D
Clin Transpl; 2009; ():499-503. PubMed ID: 20524323
[TBL] [Abstract][Full Text] [Related]
13. Successful bortezomib-based treatment in POEMS syndrome.
Tang X; Shi X; Sun A; Qiu H; Gu B; Zhou H; Xue S; Liu Y; Ruan C; Wu D
Eur J Haematol; 2009 Dec; 83(6):609-10. PubMed ID: 19674063
[No Abstract] [Full Text] [Related]
14. Clonal deletion with bortezomib followed by low or no maintenance immunosuppression in renal allograft recipients.
Trivedi HL; Terasaki PI; Feroz A; Vanikar AV; Trivedi VB; Khemchandani SI; Dave SD; Shankar V; Modi PR; Kaneku H; Idica A; Everly MJ
Transplantation; 2010 Jul; 90(2):221-2. PubMed ID: 20644455
[No Abstract] [Full Text] [Related]
15. Use of bortezomib as adjunctive therapy for densensitization in combined heart and kidney transplantation--a case report.
Patel JK; Everly MJ; Kittleson M; Kobashigawa JA
Clin Transpl; 2009; ():347-9. PubMed ID: 20524297
[No Abstract] [Full Text] [Related]
16. Bortezomib rescue in refractory acute humoral rejection--report of a case.
Shapiro R; Basu A; Zeevi A; Lunz J; Mapara M; Randhawa P; Morgan C; Tan HP; Sharma V
Clin Transpl; 2009; ():431-2. PubMed ID: 20524310
[No Abstract] [Full Text] [Related]
17. Perspective on the current use of bortezomib in multiple myeloma.
San-Miguel J; Bladé J
Haematologica; 2006 Jul; 91(7):871-2. PubMed ID: 16818272
[No Abstract] [Full Text] [Related]
18. Bortezomib as a rescue therapy for hyperacute and multi-drug resistant mixed acute rejection after kidney transplantation.
Djamali A; Muth BL; Torrealba J; Bloom D; Miller KM; Lorentzen D; Sollinger HW; Pirsch JD; Mezrich JD
Clin Transpl; 2009; ():485-90. PubMed ID: 20524320
[No Abstract] [Full Text] [Related]
19. A high-dose bortezomib neuropathy with sensory ataxia and myelin involvement.
Filosto M; Rossi G; Pelizzari AM; Buzio S; Tentorio M; Broglio L; Mancuso M; Rinaldi M; Scarpelli M; Padovani A
J Neurol Sci; 2007 Dec; 263(1-2):40-3. PubMed ID: 17612569
[TBL] [Abstract][Full Text] [Related]
20. [Bortezomib].
Simons S; Scheulen ME; Jaehde U
Dtsch Med Wochenschr; 2006 Feb; 131(5):214-8. PubMed ID: 16440269
[No Abstract] [Full Text] [Related]
[Next] [New Search]
